CEO, Owl Insights
Eric Meier has over 25 years of experience in the health care market place specifically in the development and commercialization of novel disruptive and innovative health care solutions. These solutions span software, medical devices, drug delivery, and drug compounds. He has built world class teams with deep domain knowledge in the areas of behavioral health, neuroscience, oncology, cardiovascular, and general surgery. He has extensive experience in fund raising from a variety of US, European, and Asian sources including institutional, family office, strategic, and non-profit entities. He has raised over $200 million to date and structured a variety of complex transactions.
Mr. Meier has had extensive operating experience in both large and emerging companies.
At Johnson and Johnson, he led a variety of corporate development activities focused upon identifying new markets, technologies, and company prospects at several operating companies.
In 2000, Mr. Meier founded Calypso Medical and served as its President and CEO from 2000 - 2010, a medical device company providing real time tumor tracking company for the precise delivery of external beam radiation therapy. During that period, the company raised in excess of $175M, achieved five product clearances and treated in excess of 50,000 patients. In 2011, the company was acquired by Varian Medical Systems.
In 2010, Mr. Meier joined Cervel Neurotech, a medical device company providing targeted non-invasive deep brain stimulation for psychiatric and neurologic disorders, as President and CEO. Since 2010, Cervel has completed a variety of successful clinical studies including a randomized sham controlled study for patients suffering from depression. The company has built a world class management team and raised in excess of $25M.
Mr. Meier is a member of the board of directors of the Medical Device Manufacturers Association, Doernbecher Foundation, and Ziba Design.
He is also an active angel investor.
Sr. Medical Science Liaison and Lead Scientist for Product Development, Genomind